J
Johan Aschan
Researcher at Janssen-Cilag
Publications - 81
Citations - 5207
Johan Aschan is an academic researcher from Janssen-Cilag. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 38, co-authored 80 publications receiving 5055 citations. Previous affiliations of Johan Aschan include Karolinska University Hospital & Sahlgrenska University Hospital.
Papers
More filters
Journal ArticleDOI
Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease.
Olle Ringdén,Mehmet Uzunel,Ida Rasmusson,M Remberger,Berit Sundberg,Helena Lönnies,Hanns-Ulrich Marschall,Aldona Dlugosz,Attila Szakos,Zuzana Hassan,Brigitta Omazic,Johan Aschan,L Barkholt,Le Blanc K +13 more
TL;DR: MSC is a very promising treatment for severe steroid-resistant acute GVHD and five patients are still alive between 2 months and 3 years after the transplantation and their survival rate was significantly better than that of 16 patients with steroid- resistant biopsy-proven gastrointestinal GV HD, not treated with MSC during the same period.
Journal ArticleDOI
Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis.
S Carlens,O Ringdén,M Remberger,Berit Lönnqvist,Hans Hägglund,S. Klaesson,Jonas Mattsson,Britt-Marie Svahn,Jacek Winiarski,Per Ljungman,Johan Aschan +10 more
TL;DR: Among 551 consecutive recipients of allogeneic bone marrow transplants, 451 survived more than 3 months and were evaluated for chronic graft-versus-host disease (GVHD), and high recipient age was the single most important risk factor (P < 0.001).
Journal Article
Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings.
O Ringdén,M Remberger,Persson U,Per Ljungman,A Aldener,Andström E,Johan Aschan,Per Bolme,Göran Dahllöf,Tina Dalianis +9 more
TL;DR: Among 42 consecutive recipients of unrelated marrow were 39 HLA-A, -B, -DR identical, matched unrelated donors (MUD) and three with one HLA antigen mismatch, which included 24 patients with hematological malignancies, 6 with severe aplastic anemia and 9 inherited disorders.
Journal ArticleDOI
Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients.
Per Ljungman,Johan Aschan,Ilona Lewensohn-Fuchs,S Carlens,Kajsa Larsson,Berit Lönnqvist,Jonas Mattsson,Elda Sparrelid,Jacek Winiarski,Olle Ringdén +9 more
TL;DR: Preemptive therapy based on polymerase chain reaction for CMV DNA was associated with reduced risks forCMV disease, CMV-associated death, and TRM, whereas other prophylactic modalities did not give additional benefit.
Journal ArticleDOI
Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology.
Moustapha Hassan,Gunnar Öberg,Albert N. Békássy,Johan Aschan,Hans Ehrsson,Per Ljungman,Gudmar Lönnerholm,Bengt Smedmyr,A. Taube,Inger Wallin,Bengt Simonsson +10 more
TL;DR: It is concluded that the busulphan dosage for children must be reconsidered and that further studies are urgently needed to develop an optimal therapy.